Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Latest Information Update: 30 May 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Giant cell tumours; Lung cancer; Non-small cell lung cancer; Pulmonary blastoma
- Focus Therapeutic Use
- 28 May 2024 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2017 Status changed from not yet recruiting to recruiting.